Dr. Yong Zhao will present the clinical data from Spanish clinical trial at Immunology of Diabetes Society 14th International Congress (Munich, Germany), titled “Correct the autoimmune memory by Stem Cell Educator therapy in Caucasian type 1 diabetic subjects: phase I/II clinical trial”.
Lecture at The XIII Congress of the Catalan Association of Diabetes (Barcelona, Spain).
Dr.Yong Zhao was invited and gave a lecture at The XIII Congress of the Catalan Association of Diabetes (Barcelona, Spain) about Stem Cell Educator Therapy.
Invitation to speak at the 18th Scientific Meeting of the Chinese Diabetes Society
Dr. Yong Zhao was invited as a keynote speaker and gave a lecture on “Application of Umbilical Cord Blood Stem Cells in Diabetes Management”, at the 18th Scientific Meeting of the Chinese Diabetes Society (CDS, Guangzhou, China).
Partnership with CORD:USE in Orlando, Florida
The FDA-registered cord blood bank CORD:USE in Orlando (USA) and Tianhe Stem Cell Biotechnologies enter into a Long-Term Partnership from current academic collaboration to future business collaboration on Stem Cell Educator therapy in clinic.
Approved patent on human peripheral blood stem cells
Tianhe’s patent on human peripheral blood stem cells has been granted by United States Patent Office. These autologous stem cells are suitable for the treatment of diabetes, cardiovascular diseases, neurodegenerative diseases, and others.
International patent granted in the European Union
Tianhe’s international patent on human cord blood stem cells has been granted by European Patent Office. This patent will cover the countries in European Union.
Ranked one of top 3 T1D technologies in the world
Stem Cell Educator therapy becomes one of the top 3 technologies to practically cure type 1 diabetes among over 300 current clinical trials in the world. Read more on Juvenile Diabetes Cure Alliance website: Exhibit 10 in State of the Cure 2013
New T1D clinical trial in Changsha, China
To advance Stem Cell Educator Therapy and find a cure for type 1 diabetes, a new clinical trial was initiated in children with type 1 diabetes, in collaboration with Dr.Zhiguang Zhou at the Second Xiangya Hospital of Central South University (Changsha, China) as well as the apheresis team from Terumo BCT (Denver, USA)
Phase I/II of type 2 diabetes is published in BMC Medicine
Dr.Zhao and his team published the Phase I/II clinical trial data in type 2 diabetes, at the peer review clinical journal BMC Medicine. The clinical data demonstrate the safety and efficacy of Stem Cell Educator therapy for the treatment of type 2 diabetes. Stem Cell Educator therapy opens up new avenues to find a cure for type 1 diabetes and type 2 diabetes.
Stem Cell Educator is FDA registered
Stem Cell Educator, as a new Medical Device, has been successfully registered at the United States Food and Drug Administration (FDA).
Ranked top 6 for diabetes cure
Report from Juvenile Diabetes Cure Alliance (JDCA): Stem Cell Educator therapy is one of six-leading trials targeting the practical cure of type 1 diabetes (total 332 clinical trials in T1D)
Successful T1D treatment in Spain
Dr.Zhao and his collaborative team at University of Oviedo, Hospital Universitario Central de Asturias (Spain), have successfully treated the 1st type 1 diabetic patient by using Stem Cell Educator therapy. This is an international multi-center Phase II trial approved by the Ministry of Health in Spain.
Stem Cell Educator Therapy in Alopecia Areata
In collaboration with Hebei Medical University, Tianhe starts a new clinical trial in an autoimmune-related skin disease, titled "Stem Cell Educator Therapy in Alopecia Areata".
Phase II approved in Spain
The Ministry of Health in Spain has approved the Phase II clinical trial of Stem Cell Educator therapy in type 1 diabetes.